Cinclus Pharma: Initiating pivotal phase III study - Redeye

Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase III HEEALING 1 study in severe erosive GERD. We view this as a pivotal milestone that provides clarity on the timeline and pathway to market entry of linaprazan glurate, setting the stage for significant value creation ahead.

Länk till analysen i sin helhet: https://www.redeye.se/research/1126081/cinclus-pharma-initiating-pivotal-phase-iii-study?utm_source=finwire&utm_medium=RSS